Bayer's $7.25 Billion Roundup Settlement Gets Preliminary Approval: What Law Firms Need to Know

A Missouri state court judge granted preliminary approval on March 4, 2026 for Bayer's $7.25 billion class settlement to resolve approximately 65,000 active Roundup cancer claims. The agreement, submitted in the 22nd Judicial Circuit Court in St. Louis, requires Bayer to deposit $500 million within 10 days for class notice and claims administration, followed by structured annual payments spanning 21 years.

The proposed settlement arrives as Bayer's total Roundup litigation expenses have exceeded $16 billion since its 2018 acquisition of Monsanto. Concurrently, the U.S. Supreme Court is scheduled to hear oral arguments in Monsanto v. Durnell on April 27, 2026, addressing federal preemption of state failure-to-warn claims under FIFRA.

Scope and Compensation Structure

The class settlement, announced February 17, 2026, establishes two primary claimant categories: active plaintiffs with non-Hodgkin lymphoma (NHL) claims filed prior to preliminary approval, and future qualifying claimants exposed before February 17, 2026 who receive an NHL diagnosis within 16 years of final approval.

Individual compensation ranges from $5,000 to $250,000 based on three criteria: pathology and NHL subtype, age at diagnosis, and exposure category. Occupational applicators documenting 80 or more hours of commercial, agricultural, or landscaping exposure qualify for enhanced tiers relative to residential users.

The framework differs from Bayer's 2021 proposal for a $2 billion future claims fund, which was rejected by federal Judge Vince Chhabria. The current structure was negotiated with six prominent plaintiffs' firms, including Motley Rice, Seeger Weiss, and The Holland Law Firm, establishing fixed payout schedules rather than an independent science panel.

Opposition and Intervention Motions

Fourteen law firms representing approximately 20,000 plaintiffs filed motions to intervene, challenging the accelerated approval timeline and tier distribution formulas. Intervening counsel raised objections regarding representation adequacy, allocation disparities between occupational and residential claimants, and broad scope-of-release terms.

Class counsel defended the negotiated terms as providing predictable compensation across a substantial claimant pool. Judge Boyer granted preliminary approval, establishing an opt-out window running through June 4, 2026.

Supreme Court Preemption Proceedings

The settlement timetable coincides with appellate review in the U.S. Supreme Court. The court granted certiorari in Monsanto v. Durnell to determine whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state-law failure-to-warn claims.

Oral arguments are set for April 27, 2026. The U.S. Solicitor General filed an amicus brief supporting Bayer's position that EPA label approvals preclude contradictory state-law warning obligations.

A Supreme Court ruling upholding preemption would restrict state failure-to-warn claims for plaintiffs who opt out of the class agreement, making the opt-out evaluation a critical strategic calculation.

Strategic Considerations for Law Firms

The Opt-Out Calculation

Counsel managing Roundup inventories must evaluate individual case files before June 4. The class structure offers scheduled payouts ($5,000 to $250,000), whereas individual trials have yielded both substantial plaintiff verdicts: such as the $2.25 billion McKivison verdict in Pennsylvania (remitted to $400 million) and the $2.1 billion Barnes verdict in Georgia: and defense verdicts in 14 of the last 20 trials.

A ruling favoring preemption in Durnell would substantially increase defense leverage in remaining individual trials.

Medical Documentation and Tier Qualification

Placing claims into appropriate settlement tiers requires specific clinical proof:

• Pathology reports confirming non-Hodgkin lymphoma and specific histological subtypes (e.g., DLBCL, follicular lymphoma, mantle cell lymphoma).
• Oncology records establishing diagnosis dates, staging, and treatment regimens (chemotherapy, immunotherapy, stem cell transplantation).
• Exposure documentation establishing commercial or residential application hours prior to February 17, 2026.

Reverse search uses insurance data to fill in treatment gaps clients don't always remember, surfacing facilities, dates, and clinicians as needed.

Evidentiary Priorities for Roundup Settlement Tiers

The $7.25 billion class settlement creates a structured resolution pathway for active Roundup claims. Whether a firm resolves claims within the settlement matrix or maintains individual actions, establishing verified pathology reports and detailed treatment histories is essential to maximizing recovery.

Records generally return in 4 days on average, with roughly 30-40% returned same-day on electronic requests. Because medical record retrieval is an itemized case cost, invoices flow directly onto settlement statements as recoverable disbursements.

---

Sources: Reuters, Bayer Press Release, Drugwatch, Law.com/National Law Journal, The New Lede, BusinessWire/Solicitor General Brief. Settlement terms per Bayer's February 17, 2026 filing.